№ files_lp_4_process_2_54596
File format: docx
Character count: 3675
File size: 21 KB
Employment application form used by Sickle Cell Society collecting personal details, education, employment history, health information, references, and equal opportunities monitoring data from candidates applying for a position within the organisation.
Organisation:
Sickle Cell Society
Document Type:
Job Application Form
Confidentiality:
Confidential
Country:
United Kingdom
Related Legislation:
Asylum & Immigration Act 1996
Purpose:
Application for employment position within the organisation
Sections Included:
Personal Information; Education; Employment History; Supporting Information; Health Declaration; References; Applicant Declaration; Equal Opportunities Monitoring
Equal Opportunities Data:
Sex; Ethnic Origin; Disability Status
Medical Requirement:
Possible medical examination by an approved doctor prior to employment
Applicant Declaration:
Confirmation of truthfulness of provided information and right to work in the UK
Required Attachments:
Additional sheets for supporting information if necessary
Reference Requirement:
Two referees with professional relationship to the applicant
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2019
Region / City:
UK
Topic:
Hematology, Sickle Cell Disease, Blood Transfusion
Document Type:
Guideline
Author:
Dr Elizabeth Rhodes, Dr Julia Sikorska
Target Audience:
Medical staff involved in the care of patients with Sickle Cell Disease
Period of Validity:
2019–2022
Approval Date:
14th February 2019
Review Date:
February 2022
Version:
1.0
Review date:
May 2026
Adapted from:
RDTC shared care protocol version 1.1 (October 2023, updated March 2024)
Replaces:
GMMMG Shared Care Protocols for Hydroxycarbamide in adult sickle cell disease and adult myeloproliferative disease (17/8/2017, Version 2.1)
Local approval date:
22.02.2024 (local content added)
CRG approval date:
09.04.2024
GMMMG approval date:
09.05.2024
CEGC approval date:
23.05.2024
Intended users:
NHS healthcare professionals
Target population:
Adults aged 18 and over with myeloproliferative disorders or sickle cell disease
Licensed indications:
Chronic myeloid leukaemia; Essential thrombocythaemia; Polycythaemia vera; Sickle-cell disease
Off-label indications:
Primary myelofibrosis; Unclassified myeloproliferative disorders; Psoriasis
Treatment setting:
Shared care between specialist and primary care (transfer after ≥12 weeks when stable)
Initiation responsibility:
Specialist
Prescribing transfer:
Primary care after stabilisation and satisfactory results
Dose range (initial):
Essential thrombocythaemia 15 mg/kg daily; Polycythaemia vera 15–20 mg/kg daily; Sickle-cell disease 15 mg/kg daily with 5 mg/kg steps
Maintenance dose range (sickle-cell disease):
15–30 mg/kg daily (max 35 mg/kg)
Dose adjustment considerations:
Elderly, renal impairment (CrCl ≤60 mL/min start reduced by 50%), myelotoxicity
Baseline investigations:
FBC, U&Es/eGFR or CrCl, LFTs, viral screening, lung disease screening (clinician discretion), vaccination status
Additional sickle-cell baseline:
Reticulocyte count
Monitoring frequency (primary care):
Every 8–12 weeks (FBC, U&Es, LFTs, reticulocyte count for sickle-cell disease)
Ongoing specialist monitoring:
Usually annually; specialist retains responsibility for treatment response and dose changes
Vaccination note:
Shingles vaccine eligibility for ages 50–79 (refer to Green Book)
Shared care protocol type:
Clinical prescribing and monitoring guideline
Year:
2024
Region / city:
Liverpool
Topic:
Sickle cell crisis, Aplastic crisis
Document type:
Informational leaflet
Author:
Not specified
Target audience:
Parents and carers of children with sickle cell disease
Period of validity:
Until review date
Approval date:
Not specified
Date of changes:
April 2024
Note:
Year
Topic:
Sickle Cell Anemia, Medical History, Treatment
Document Type:
Educational Activity
Year:
Current school year
Revision date:
January 2020
Organization:
Duplin County School System
Department:
Student Health Services
Document type:
School emergency health plan
Medical condition:
Sickle Cell Anemia Disorder
Intended location of use:
School setting
Target individuals:
Student with Sickle Cell Anemia, school staff, parents/guardians
Required signatures:
Parent/Guardian, School Nurse
Parental consent included:
Yes
Medical information release authorization:
Included
Distribution:
Teachers, office personnel, bus driver, emergency responders
Filing instruction:
File original in IHR; copies to appropriate staff and Emergency Action Plan Notebook
Year:
Not specified
Country of origin:
Surinam
Institution:
The Hemoglobin University
Authors:
Bento C; Traeger-Synodinos J; Kountouris P; et al.
Thematic area:
Hematology; Hemoglobinopathies; Molecular genetics
Document type:
Case report submission form
Gene:
HBB
Protein variant:
p.Glu7Val
cDNA variant:
c.20A>T
Variant name:
HbS
Database accession:
HbVar ID 226; IthaID 824
Phenotype:
Abnormal Doppler; organ failure due to vaso-occlusive crisis; skeletal dysplasia
Alpha genotype:
-alpha3.7/-alpha3.7
Beta genotype:
betaS/betaS
Age at evaluation:
56 years
Age at diagnosis:
2 months
Sex at birth:
Female
Family history:
Two sisters carriers of HbS
Clinical history:
Hydroxyurea treatment from childhood until 54 years; uncomplicated pregnancy at 23 years; exchange transfusion started at 54 years
Hematological parameters before transfusion:
Reported at age 53 years (Hb, MCV, MCH, RBC, Hct, Ret, RDW)
Iron status:
Ferritin 35 µg/L
Blood smear:
Target cells at normal iron indicative of alpha-thalassemia trait
Biochemical studies:
Capillary electrophoresis (Sebia); HPLC (Trinity PHR)
Molecular studies:
Sanger sequencing of exon 1 of HBB gene
Transfusion status:
Exchange transfusion from age 54 years
Year:
2026
Field:
Genetics / Molecular Biology
Document Type:
Laboratory Exercise
Institution:
University / Educational Laboratory
Target Audience:
Undergraduate Biology Students
Learning Objectives:
Phenotypic analysis, genotypic analysis, molecular mechanisms, inheritance patterns, treatment planning
Methods:
Microscopy, DNA/RNA modeling, case study analysis
Disorder Focus:
Sickle Cell Anemia
End Product:
Lab report with drawings and answers to guided questions
Duration:
One laboratory session
Assessment:
Comparison of phenotypes, explanation of gene expression, transcription modeling
Year:
2026
Organization:
Sickle Cell Society
Document Type:
Job Application Form
Position Applied For:
[To be filled by applicant]
Applicant Information:
Name, Address, Date of Birth, Contact Details
Education:
Schools, Colleges, Universities, Qualifications
Employment History:
Current and Previous Employment Details
Health Information:
Medical History, Days Absent
References:
Two Professional References Required
Declaration:
Applicant Signature and Date
Equal Opportunities Monitoring:
Sex, Ethnic Origin, Disability Status, Recruitment Source
Year:
2026
Organization:
Sickle Cell Society
Document Type:
Job Application Form
Position Applied For:
[to be filled by applicant]
Applicant Name:
[to be filled by applicant]
Date of Birth:
[to be filled by applicant]
Contact Information:
[to be filled by applicant]
Education:
[to be filled by applicant]
Employment History:
[to be filled by applicant]
Health Information:
[to be filled by applicant]
References:
[to be filled by applicant]
Declaration Date:
[to be filled by applicant]
Jurisdiction:
United Kingdom
Note:
Year
Topic:
Medical assessment
Document type:
Questionnaire
Target audience:
Medical professionals
Year:
2026
Organization:
Sickle Cell Society
Document Type:
Job Application Form
Position Applied For:
[Blank field]
Target Audience:
Job applicants
Region:
United Kingdom
Required Documents:
Proof of right to work in the UK
Health Information:
Applicant to declare serious illnesses and absences
References:
Two referees required, one current employer
Date:
[Date field]
Year:
2026
Region / City:
United Kingdom
Subject:
Employment Application
Document Type:
Job Application Form
Organization:
Sickle Cell Society
Position Applied For:
[Not specified]
Applicant Name:
[To be filled by applicant]
Education:
[To be filled by applicant]
Employment History:
[To be filled by applicant]
Health Information:
[To be filled by applicant]
References:
[To be provided by applicant]
Declaration:
Applicant confirms truthfulness of provided information and compliance with UK work eligibility requirements
Year:
2025
Region / City:
Washington, D.C.
Topic:
Drug Development, Clinical Trials, Sickle Cell Disease
Document Type:
Press Release
Organization / Institution:
Sickle Cell Medical Advocacy Inc., Sickle Cell Foundation of Georgia, Inc., Sickle Cell Disease Association of America Inc., Crescent Foundation, SC RED, Sickle Cell 101, Sickle Cell Community Consortium
Author:
Sickle Cell Advocates
Target Audience:
Sickle Cell Disease Community, Medical Researchers, Pharmaceutical Industry
Effective Period:
August 15, 2025
Approval Date:
August 15, 2025
Date of Changes:
N/A
Note:
Contextual Description
Year:
2024
Region / City:
Liverpool
Topic:
Sickle Cell Disease, Respiratory Care
Document Type:
Information Leaflet
Author:
Not specified
Target Audience:
Parents and Carers of Children with Sickle Cell Disease
Effective Period:
Indefinite, subject to review
Approval Date:
June 2028
Modification Date:
Not specified
Year:
2023
Region:
Asia
Topic:
Oncology, Rare Renal Tumors
Document Type:
Case Report
Institution:
Unspecified Medical Institute
Author:
Unspecified
Patient Age:
36
Patient Sex:
Male
Clinical Presentation:
Hematuria, Flank Pain
Diagnosis:
Renal Medullary Carcinoma, SMARCB1 mutation, Sickle Cell Trait
Treatment:
Nephrectomy, Chemo-immunotherapy (Gemcitabine, Carboplatin, Pembrolizumab), Palliative Radiation
Outcome:
Initial complete metabolic response, progression after 1 year, patient deceased
Keywords:
Renal Medullary Carcinoma, Sickle Cell Trait, Clinical Trials, Young Males, Aggressive
Clinical Trial Eligibility:
Recommended
Histopathology:
Loss of INI1 expression, Central renal medulla infiltration, Metastatic disease
Imaging:
PET-CT confirmed renal lesion, lymph node enlargement, pulmonary and bone metastases
Year:
2021
Region / City:
California
Topic:
Hydrogen Fuel Cell Vehicles, Zero-Emission Technology
Document Type:
Grant Funding Opportunity
Agency / Institution:
California Energy Commission
Author:
California Energy Commission
Target Audience:
Research institutions, businesses, and entities involved in heavy-duty vehicle technology development
Period of Validity:
2021-2025
Approval Date:
July 2021
Modification Date:
Not specified
Year:
2023
Region / City:
Chicago, USA
Topic:
Enhancements on cell DTX/DRX mechanism
Document Type:
Discussion Summary
Organization / Institution:
3GPP TSG RAN WG1
Author:
Moderator (Intel Corporation)
Target Audience:
3GPP TSG RAN WG1 Participants
Period of Validity:
November 13th – 17th, 2023
Approval Date:
Not specified
Date of Changes:
Not specified
Document type:
Normative technical requirements document
Standard reference:
ECSS-E-ST-20-08
Related standards:
ECSS-E-ST-10
Abbreviation:
SCD-BSC
Applicable domain:
Space solar cell hardware
Subject matter:
Bare solar cell qualification and acceptance requirements
Scope:
Project-dependent requirements for bare solar cells
Input to:
Qualification plan
Cell types covered:
Silicon solar cells; single- and multi-junction III-V solar cells
Test categories:
Acceptance tests; qualification tests
Key technical areas:
Materials; dimensions and weight; electrical performance; optical properties; environmental tests; mechanical tests
Source authority:
European Cooperation for Space Standardization
Intended use:
Specification and control of bare solar cell characteristics
Year:
2021
Region / City:
Australia
Topic:
Biologicals, Human Cell and Tissue Products, Donor Screening
Document Type:
Guideline
Agency:
Therapeutic Goods Administration (TGA)
Author:
Therapeutic Goods Administration (TGA)
Target Audience:
Manufacturers and Sponsors of Biological Products
Effective Period:
2021
Approval Date:
May 2021
Amendment Date:
N/A
Year:
2019
Region / City:
UK
Topic:
Hematology, Sickle Cell Disease, Blood Transfusion
Document Type:
Guideline
Author:
Dr Elizabeth Rhodes, Dr Julia Sikorska
Target Audience:
Medical staff involved in the care of patients with Sickle Cell Disease
Period of Validity:
2019–2022
Approval Date:
14th February 2019
Review Date:
February 2022